In a nutshell This study investigated the effectiveness and safety of bevacizumab (Avastin) combined with chemotherapy in elderly patients with advanced colorectal cancer. Researchers suggested that this therapy might be associated with improved outcomes in fit older patients. Some background Colorectal cancer is the third most common cancer...
Read More
In a nutshell This study aimed to investigate the safety and effectiveness of tucatinib in combination with trastuzumab and capecitabine in patients with HER2 positive metastatic breast cancer who have had disease progression with other treatments. This study concluded that this treatment combination was safe and...
Read MoreIn a nutshell This study aimed to investigate the outcome of early switching from imatinib to dasatinib of patients with chronic-phase chronic myeloid leukemia with weak responses to imatinib treatment. The study concluded that this switch may offer clinical benefit in certain patients. Some background Imatinib...
Read More
In a nutshell This study examined if non-insulin drug lixisenatide (Lyxumia) boosted treatment results from insulin glargine (Lantus) in patients with uncontrolled type 2 diabetes (T2D). Patients who received lixisenatide and glargine had improved blood glucose control and no significant increase in side effects. Some background Uncontrolled...
Read More
In a nutshell This study examined the effectiveness and safety of immunotherapy before stem cell transplantation (SCT) in patients with Hodgkin lymphoma (HL). The authors concluded that this therapy increased the time before HL worsened and did not increase side effects. Some background Immunotherapy, including anti-PD-1 treatment such as...
Read More
In a nutshell This study investigated if a single-pill combination (SPC) improves clinical outcomes in patients with high blood pressure (BP) and high cholesterol levels. They found that SPC improved medication adherence and outcomes of these patients. Some background Hypertension or high blood pressure (BP) is a common condition. Hypertension...
Read More
In a nutshell This study investigated the effectiveness of Janus kinase (JAK) inhibitors in rheumatoid arthritis (RA). They found that JAK inhibitors were more effective than conventional RA drugs. Some background Rheumatoid arthritis (RA) is a chronic immune condition. RA causes painful inflammation in the joints. This leads to disability...
Read MoreIn a nutshell The study evaluated treatment outcomes in patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) who continued blinatumomab (Blincyto; BL) after initial therapy. The authors found that long-term BL therapy can improve survival in these patients. Some background 45% of adults with ALL experience R/R...
Read More
In a nutshell The study examined whether health-related quality of life (HRQoL) relates to the molecular response (MR) to tyrosine kinase inhibitors (TKIs) in patients with chronic-phase chronic myeloid leukemia (CP-CML). The authors found that improved MR had differential effects on HRQoL in such patients. Some background TKIs are a treatment used...
Read More
In a nutshell This study looked at the relationship between kidney function and hypoglycemia in patients with diabetes. It found that patients with low kidney function had hypoglycemia more frequently, and the episodes were more severe. Some background Diabetes is a disorder leading to high levels of glucose (sugar) in the blood. High levels of...
Read More
In a nutshell This study examined how common depression and anxiety are amongst patients with Hodgkin lymphoma (HL) compared to the general population. The authors found that more medications for depression or anxiety are prescribed to patients with HL than to the general population. Some background Patients who develop or recover from cancer...
Read More
In a nutshell This trial looked at the quality of life (QOL) of patients receiving PVd (pomalidomide, bortezomib, dexamethasone) for multiple myeloma which has returned after previous treatment. This study showed that adding pomalidomide (Pomalyst) to the Vd regimen (bortezomib, dexamethasone) did not decrease patients' QOL. Some background...
Read More
